ATE61000T1 - Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren. - Google Patents

Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.

Info

Publication number
ATE61000T1
ATE61000T1 AT84108838T AT84108838T ATE61000T1 AT E61000 T1 ATE61000 T1 AT E61000T1 AT 84108838 T AT84108838 T AT 84108838T AT 84108838 T AT84108838 T AT 84108838T AT E61000 T1 ATE61000 T1 AT E61000T1
Authority
AT
Austria
Prior art keywords
target
antibody
methods
remove non
specific diagnostic
Prior art date
Application number
AT84108838T
Other languages
English (en)
Inventor
Milton David Goldenberg
Original Assignee
Milton David Goldenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24065160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE61000(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Milton David Goldenberg filed Critical Milton David Goldenberg
Application granted granted Critical
Publication of ATE61000T1 publication Critical patent/ATE61000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT84108838T 1983-07-29 1984-07-26 Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren. ATE61000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51871383A 1983-07-29 1983-07-29
EP84108838A EP0149709B2 (de) 1983-07-29 1984-07-26 Verfahren zur Erhöhung der Zielspezifizität in Antikörperbestimmungen und zur Räumung von nichtzielspezifischen diagnostischen und therapeutischen Faktoren

Publications (1)

Publication Number Publication Date
ATE61000T1 true ATE61000T1 (de) 1991-03-15

Family

ID=24065160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84108838T ATE61000T1 (de) 1983-07-29 1984-07-26 Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.

Country Status (9)

Country Link
EP (1) EP0149709B2 (de)
JP (2) JPH062678B2 (de)
AT (1) ATE61000T1 (de)
AU (1) AU568138B2 (de)
CA (1) CA1244760A (de)
DE (1) DE3484198D1 (de)
IL (1) IL72519A (de)
WO (1) WO1985000522A1 (de)
ZA (1) ZA845863B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577781B2 (en) * 1983-04-28 1988-10-06 Mark Philip Best Lung imaging with radiolabelled agents
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
GB8525974D0 (en) * 1985-10-22 1985-11-27 Nyegaard & Co As Chemical substance
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
FR2620803B1 (fr) * 1987-09-21 1990-01-12 Chaffoteaux Et Maury Perfectionnements aux ballons d'eau chaude
US5084266A (en) * 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
CA1339415C (en) * 1989-08-24 1997-09-02 Milton David Goldenberg Detection and treatment of infections with immunoconjugates
KR0162259B1 (ko) * 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
DK176290D0 (da) * 1990-07-24 1990-07-24 Novo Nordisk As Terapeutisk og diagnostisk praeparat
CA2062582C (en) * 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US6685930B1 (en) 1991-03-27 2004-02-03 Tanox, Inc. Methods and substances for recruiting therapeutic agents to solid tumors
CN1221250C (zh) * 1998-04-09 2005-10-05 阿莫萨姆保健公司 微粒造影剂在研究生理参数的诊断成像中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4334017A (en) * 1979-04-16 1982-06-08 Massachusetts Institute Of Technology Method for detecting cancer in mammalian tissue
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody

Also Published As

Publication number Publication date
JPS60501906A (ja) 1985-11-07
JPH06312944A (ja) 1994-11-08
EP0149709B2 (de) 1995-11-29
IL72519A (en) 1989-06-30
AU3129684A (en) 1985-01-31
EP0149709B1 (de) 1991-02-27
WO1985000522A1 (en) 1985-02-14
CA1244760A (en) 1988-11-15
ZA845863B (en) 1985-04-24
IL72519A0 (en) 1984-11-30
AU568138B2 (en) 1987-12-17
EP0149709A1 (de) 1985-07-31
DE3484198D1 (de) 1991-04-04
JPH0747549B2 (ja) 1995-05-24
JPH062678B2 (ja) 1994-01-12

Similar Documents

Publication Publication Date Title
ATE61000T1 (de) Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.
ATE177321T1 (de) Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
EP0335910A4 (de) Intraoperative erstellung des befundes und tumor-therapie mittels endoskop.
DE3876052D1 (de) Medizinische verwendung.
DE3788961D1 (de) Verfahren zur herstellung von polysubstituierten diethylentriaminpentaessigsäuren.
LU91498I2 (fr) Etanercept et ses dérivés pharmaceutiquement acceptables.
DE3485649D1 (de) Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.
DE69014137D1 (de) Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
NO974275D0 (no) Fremgangsmåte for behandling av tumorer
EP0261224A4 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
IL68201A0 (en) Peptides with the specificity of foot and mouth disease viral antigens and compositions and methods for treating animals using the same
DE3855527D1 (de) Doppelsträngige RNS zur Korrektur von Abnormalitäten von zirkulierenden Immunkomplexen und der Monozytenfunktion
SU556805A1 (ru) Способ введени лекарственных веществ
FI924363A0 (fi) Foerfarande foer behandling och/eller diagnostisering av mjukvaevnadstumoerer.
SE9103837L (sv) Fluorescensdiagnostik av cancer utnyttjande delta- aminolevulinsyra
DE69026371D1 (de) Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
DE68919758D1 (de) Antikörper gegen Fibrin, Immunogen zur Herstellung desselben, Verfahren zur Bestimmung von Fibrin und pharmazeutisches Präparat auf Basis der Antikörper.
SU566036A1 (ru) Крестово-кулисна муфта
SU580936A1 (ru) Заготовка дл гидростатического прессовани полых изделий
SU592804A1 (ru) Способ обработки бетонной смеси
DK377588D0 (da) Anvendelse af en vehikel med hoej affinitet til tumorer
SU662336A1 (ru) Способ изготовлени абразивного инструмента
ATE50870T1 (de) Sero-immunologisches verfahren zur in-vivo feststellung der wirksamkeit cytostatischer mittel.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee